Introduction
Heart failure (HF) is a rapidly growing global public health problem in advanced nations with estimated prevalence of > 37.7 million cases worldwide [1] . Despite the significant achievements in treatment, the incidence, morbidity, and mortality of HF remain substantial. The lipotoxicity due to excessive serum free fatty acids (FFA) by chronic adrenergic stimulation is thought to be a mechanism of clinical deterioration in HF [2] . In contrast, unsaturated fatty acids, especially n3-polyunsaturated fatty acids (n3-PUFAs) such as eicosapentaenoic acid (EPA), have been reported to have beneficial effects against cardiovascular diseases.
Various studies have suggested that n-3 PUFAs provide cardiac protection through anti-inflammatory effects against the eicosanoidinduced vascular inflammation, changes in intracellular energeticsubstrate utilization, and alteration of phospholipid bilayer components in cell membranes. Meanwhile, investigations have also revealed pleiotropic effects of n-3 PUFAs as modulators of intracellular signaling pathways that contribute to cardiovascular protection [3] from ischemia [4] , arrhythmia [5] , and HF [6, 7] . Nevertheless, precise molecular mechanisms, by which n3-PUFAs, cause cardiac protection are not fully understood.
Mitochondria are dynamic organelles and show constant fusion and fission. Mitochondrial dynamics contribute to cellular homeostasis, and are regulated by mitochondrial fusion related proteins (mitofusin 1: Mfn1, mitofusin 2: Mfn2, and optic atrophy 1: Opa1) and by the fission related proteins (dynamin-related protein-1: Drp1, mitochondrial fission 1 protein: Fis1, and mitochondrial fission factor: MFF) [8] . A high fusion-to-fission ratio leads to mitochondrial elongation and formation of interconnected networks, whereas a low ratio results in fragmented discontinuous mitochondria. Aberrant mitochondrial dynamics are reported to correlate with the various cardiovascular diseases [9, 10] . On the other hands, the relation between cardiac lipotoxicity and aberrant mitochondrial dynamics is still elusive, and little is known about the contribution of mitochondrial dynamics proteins to EPA-mediated cardiac protection. Thus, the present study was designed to explore the molecular mechanisms of EPA-mediated cardiac protection from lipotoxicity and the contribution of mitochondrial dynamics to EPA-mediated cardiac protection using H9c2 cardiomyocytes.
Impaired intracellular metabolism disturbs an adequate energy supply for cellular homeostasis and contractions in a failing myocardium. For this reason, stimulation of AMP-activated protein kinase (AMPK), the key member of a well-known cell survival pathway, is believed to protect myocardium through an improvement of energy utilization, enhancement of mitochondrial biogenesis, and an inhibition of cell apoptosis [11] . Furthermore, a recent study by Li et al. suggested that pharmacological activation of AMPK prevents palmitate (PAL)-induced mitochondrial fragmentation and dysfunction in endothelial cells [12] . Nonetheless, the causal relation between AMPK and EPA-mediated cardiac protection is still elusive. Thus, we tested whether EPA can stimulate AMPK to protect myocytes from lipotoxicity, and studied the causal relation between AMPK activation and regulation of mitochondrial dynamics.
Materials and methods

Cell culture, differentiation, and treatment
H9c2 rat cardiac myoblasts were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in a growth medium, consisting of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% of fetal bovine serum (FBS), 2 mM glutamine, 1 mM pyruvate, 100 U/mL penicillin, and 100 µg/mL streptomycin, in humidified air (5% of CO 2 ) at 37°C. As previously reported [13] , differentiated H9c2 myocytes were produced by treating H9c2 myoblasts with a differentiation medium for 5-7 days. To promote lipotoxicity, PAL (400 μM, saturated fatty acid; Wako Pure Chemical Industries, Ltd., Osaka, Japan) was applied in the absence or presence of EPA (50 μM, n-3 PUFA; Nu-Chek Prep Inc, Elysian, MN, USA) with incubation for 24 h, as reported elsewhere [13, 14] . AMP kinase was activated by incubating cells with 2 mM 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR; Cell Signaling Technology, Inc., Beverly, MA, USA) for 24 h. GW9508 (50 μM: FOCUS Biomolecules, Plymouth Meeting, PA, USA) was added to the medium as a stimulator of GPR120 which is known as an n-3 PUFA-specific receptor on the cell membrane.
A terminal deoxynucleotidyl transferase-mediated dUTP nickend-labeling (TUNEL) assay
Apoptosis was assessed by TUNEL assay according to the manufacturer's instructions (Dead End™ Fluorometric TUNEL System, Promega, Madison, WI, USA), and propidium iodide (PI) was used for all cell staining after permeabilization with 0.2% of Triton X-100. Signal detection was performed by means of a fluorescence microscope (EVOS™fl Digital Inverted Fluorescence Microscope, Fisher Scientific, Paisley, Scotland, UK), and 100-150 cells from 10 to 20 random visual fields were evaluated in each condition.
2.3. Quantification of caspase 3 and 7 activities, ATP, mitochondrial membrane potential (ΔΨ m ), and reactive oxygen species (ROS)
The caspase 3 and 7 activities (Caspase-Glo® 3/7 Assay, Promega, Madison, WI, USA) and the intracellular ATP concentration ("Cell" ATP Assay Reagent, Toyo Ink Co., Ltd., Tokyo, Japan) were evaluated by a luciferase assay, and the luminescence data were recorded using the Molecular Imager ChemiDoc™ system (Bio-Rad Laboratories, Hercules, CA, USA).
ΔΨ m was measured by a JC-10 assay (5 mg/mL; AAT Bioquet, Sunnyvale, CA, USA), and intracellular ROS were quantified by CM-DCFDA (5 μM; Thermo Fisher Scientific, Waltham, MA, USA). The fluorescence intensity of each dye was measured on a microplate reader (Synergy HT; BioTek Instruments, Inc., Winooski, VT, USA). JC-10 was excited at 485/20 nm and 530/25 nm, and the emission signals were collected with 528/20 nm and 590/35 nm band-pass filters. CM-DCFDA was analyzed at 485/20 nm excitation and with a 528/20 nm band-pass emission filter.
DNA constructs, reagents, and transfection into differentiated H9c2 myocytes
To evaluate the mitochondrial morphology, some myocytes were transfected with mitochondrial YFP (Clontech Laboratories, Inc., Mountain View, CA, USA). Transfection of cDNA into the differentiated H9c2 myocytes was performed employing Lipofectamine LTX reagent (Life Technologies Corporation, Carlsbad, CA, USA), and the experiments were conducted 72 h after transfection according to the study protocol.
The small interfering RNA (siRNA) target sequences of the rat Drp1 gene were designed using the TAKARA siRNA Design Support System (http://www.takara-bio.com) as described previously [15] . The siRNA oligonucleotides against AMPKα1 and AMPKα2 genes were purchased from the Life Technologies Corporation. The target sequences of those siRNAs were (1) 5′-CCUCAGUAUUUGAA UCCCUCUGUAA-3′, (2) 5′-UUACACAGGGAUUCAAAUACUGAGG-3′ and (1) 5′-CACUGGUUCUUUGACUGGCAGCACU-3′, (2) 5′-AGUGCUGCCAGUCAAAGAACCAGUG-3′, respectively. The scrambled control siRNA was designed to target the following sequence: (1) 5′-CCGUCCGCAUUAGUAGCGGTT-3′ and (2) 5′-CCGCUACUAAUGCGGACGGTT-3′. The siRNAs were transfected into the differentiated H9c2 myocytes, employing Lipofectamine RNAiMAX reagent (Life Technologies Corporation), and the siRNA-expressing myocytes were analyzed 48-72 h after transfection.
Assessment of mitochondrial morphology
The mitochondrial morphology was evaluated in the mitochondrial-YFP-expressing myocytes or myocytes that were stained with MitoTracker Red CMXRos (50 nM; Thermo Fisher Scientific). Images were acquired by means of a laser-scanning confocal microscope (LSM5 PASCAL, Carl Zeiss AG, Oberkochen, Germany), which was equipped with a Kr/AR-ion laser source (488 and 568 nm excitation) and coupled to an inverted microscope (Ax overt 200 M, Carl Zeiss AG) with a 63x water-immersion objective lens [(NA)=1.2: Carl Zeiss AG]. The alterations in mitochondrial morphology were evaluated as reported elsewhere [16] . More than 100 cells from 10 to 20 random visual fields in each condition were manually classified as follows: normal (mixture of round and shorter tabulated mitochondria), fragmented (more than 50% of mitochondria were small and round), and elongated (more than 50% of mitochondria showed an elongated shape and higher interconnectivity).
Western blot analysis
Western blot analysis was performed as previously described [13] . In some experiments, β-actin or GAPDH was probed on the same membrane as a loading control. The anti-Drp1, anti-Fis1, and anti-β-actin antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), the antibody against cleaved caspase 3, caspase 3, ) phosphorylated-Drp1, and GAPDH were acquired from Cell Signaling Technology, Inc. The antibody against Mfn1, Mfn2, MFF, OPA1 were purchased from Abcam (Cambridge, UK), and HRP-conjugated secondary antibodies from Promega (Madison, WI, USA). The immunoblotting was performed with an enhanced chemiluminescence system (Thermo Fisher Scientific). The densitometric analysis was performed using the Molecular Imager ChemiDoc™ system (Bio-RAD Laboratories, Hercules, CA, USA).
Statistics
All the experiments were performed with more than three different preparations. The data are presented as mean ± SEM, and the significance of the differences was assessed by t-tests for comparison of two groups or one-way ANOVA with Tukey's post-hoc analysis for multiple comparisons. Differences with P-values < 0.05 were considered statistically significant.
Results
EPA ameliorates the PAL-induced lipotoxicity and mitochondrial dysfunction
In this series of experiments, PAL (400 µM, a saturated fatty acid) was incubated with the cells for 24 h to mimic lipotoxicity during HF [17] . In agreement with other reports [18] [19] [20] , the treatment with PAL caused a significant increase in the number of TUNEL-positive apoptotic cells as compared with the control, whereas co-incubation of the cell with EPA (50 µM) and PAL suppressed the PAL-induced apoptosis ( Fig. 1A and B) . The PAL-induced apoptosis was further examined by analysis of cleaved caspase 3 ( Fig. 1C and D ) and the activities of caspases 3 and 7 ( Fig. 1E) . Consistent with the TUNEL assay results, the activities of caspases 3 and 7 increased after PAL treatment, and the co-incubation of the cells with EPA and PAL suppressed the cleavage of caspase 3 and activation of caspases 3 and 7 by PAL. These results suggested that EPA ameliorated the PALinduced apoptosis.
We next assessed the effect of EPA on the PAL-induced mitochondrial dysfunction. PAL depolarized ΔΨ m ( Fig. 2A ) and decreased intracellular ATP (Fig. 2B) , whereas co-incubation of the cells with EPA and PAL attenuated the PAL-induced ΔΨ m depolarization and ATP depletion. In addition, EPA suppressed the upregulation of intracellular ROS caused PAL treatment (Fig. 2C ). These data suggested that EPA alleviated the PAL-induced mitochondrial dysfunction.
EPA affects mitochondrial dynamics via Drp1
Because it is well known that mitochondrial dynamics play an important role in cellular homeostasis [8] , we next analyzed mitochondrial dynamics in the PAL-treated myocytes. As we reported previously [15] , PAL induced significant mitochondrial fragmentation ( Fig. 3A and B). In contrast, the co-incubation of the cells with EPA and PAL attenuated the PAL-induced mitochondrial fragmentation. Western blot analyses of mitochondrial dynamics related proteins ( Fig. 3C : Drp1, Fis1, MFF, Mfn1, Mfn2, and OPA1) revealed that the expression level of Drp1 (a mitochondrial fission related protein) was significantly increased in the PAL-treated myocytes. In contrast, although Fis1 and MFF exhibited slight decrease, the alterations of other mitochondrial dynamics related proteins (Fis1, MFF, Mfn1, Mfn2, and OPA1) were not statistically significant in our experimental condition, as we reported previously [15] . Of note, EPA alone enhanced mitochondrial elongation (Fig. 3A) , and suppressed Drp1 expression (Fig. 3C) . Thus, our results point to the possible contribution of Drp1 to the EPAinduced protection of myocytes from adverse effects of PAL.
Because other studies have shown that Drp1 is one of key regulators of apoptosis [8] , we have also assessed the contribution of Drp1 to the PAL-induced apoptosis using the Drp1-siRNA-expressing myocytes. The knockdown of Drp1 by siRNA (Supplemental Fig. S1A ) inhibited the PAL-induced mitochondrial fragmentation (Supplemental Fig. S1B and C), caspase-3 and 7 activation (Supplemental Fig. S1D ), and intracellular ATP depletion (Supplemental Fig. S1E ). These results suggested that Drp1 is one of the key regulators of the PAL-induced apoptosis in our experimental condition.
AMPK attenuated PAL-induced lipotoxicity and mitochondrial fragmentation
On the basis of the results of other studies [21] [22] [23] , we next focused on the contribution of major cell survival pathways, including AMPK, ERK1/2, AKT, and p38, to EPA-mediated protection of myocytes. As shown in Fig. 4A , the EPA-treated myocytes showed a significant increase in phosphorylation of AMPK (Thr ; Fig. 4C ) decreased in the PAL-treated myocytes, whereas it was restored by the co-incubation with EPA. Nevertheless, EPA alone did not exhibit any alteration either in phosphorylation of ERK1/2 or AKT comparing with CTL ( Fig. 4B and C) , these results suggested that EPA may not, at least directly and/or primary, protect myocytes from PALinduced injury through these pathways. As for the p38, phosphorylation was not changed both in the PAL-and EPA-treated myocytes (Fig. 4D) . Thus, we assumed that the phosphorylation of AMPK is a possible regulatory mechanism of EPA-mediated myocyte protection.
The protective effect of AMPK against the PAL-induced lipotoxicity was further elucidated by pharmacological activation of AMPK. AICAR activated phosphorylation of AMPK ( Fig. 5A and B) and resulted in suppression of the PAL-induced caspase-3 and 7 activation (Fig. 5C ), ATP depletion (Fig. 5D) , and ROS production (Fig. 5E ). These data suggested that pharmacological activation of AMPK protected myocytes from PAL-induced apoptosis and mitochondrial dysfunction.
The activation of AMPK by AICAR also attenuated the mitochondrial fragmentation ( Fig. 6A and B ) and the expression of Drp1 increased by PAL (Fig. 6C ). Of note, AICAR alone significantly suppressed Drp1 and tended to elongate mitochondria just as EPA did. Thus, in line with our experiments on EPA, pharmacological activation of AMPK not only protected myocytes from lipotoxicity but also suppressed mitochondrial fragmentation and Drp1 expression.
EPA protected myocytes from PAL-induced lipotoxicity through activation of AMPK
We finally studied the relation between the activation of AMPK and EPA-induced protection of myocytes using AMPK-siRNA-expressing myocytes. The knockdown of AMPK by siRNA generally increased expression levels of Drp1 even in the no treatment control (Fig. 7A and  B) . In addition, EPA did not attenuate either cleavage of caspase 3 (Fig. 7C) or ATP depletion (Fig. 7D) by PAL in the AMPK-siRNAexpressing myocytes, whereas the EPA-induced protections from PAL were seen in the Scr-siRA-expressing myocytes. These results suggested that the suppression of AMPK by siRNA abrogated the EPAinduced protection of myocytes from adverse effects of PAL and that phosphorylation of AMPK may mediate the beneficial effects of EPA via Drp1 downregulation in our experimental settings.
Discussion
In this study, we used the PAL-treated H9c2 myocytes and explored the effects of EPA on PAL-induced lipotoxicity. The main findings of our current experiments are as follows: (1) EPA protected myocytes from the PAL-induced apoptosis and mitochondrial dysfunction, (2) EPA suppressed Drp1 expression and the consequent mitochondrial fragmentation, thus protecting myocytes from PAL-induced lipotoxicity, and (3) EPA may protect myocytes from the adverse effects of PAL through the activation of AMPK which resulted in Drp1 downregulation.
EPA ameliorates the lipotoxicity and mitochondrial dysfunction after treatment of PAL
Although PAL (a saturated fatty acid) is the main component of serum FFAs, it is known as one of the major apoptosis inducers [24, 25] . During HF, an increased serum FFA level due to hyperadrenergic state is believed to worsen heart function [2] . Furthermore, it is reported that ΔΨ m depolarization and ROS production under the influence of PAL further worsen mitochondrial function and cause myocardial damage [26] . Thus, we exposed differentiated H9c2 myocytes to PAL to mimic lipotoxicity during HF.
In line with other reports [24] [25] [26] , our current results revealed that PAL activated DNA laddering, activation of caspases 3 and 7, and cleavage of caspase 3 in differentiated H9c2 cardiomyocytes (Fig. 1) , thus pointing to PAL-induced apoptosis. In addition, PAL induced mitochondrial membrane depolarization, ATP depletion, and ROS production (Fig. 2) , which are suggestive of mitochondrial dysfunction caused by PAL. Protective effects of EPA against the PAL-induced apoptosis have been reported for various types of tissues and cells both in vivo [27] and in vitro [27, 28] . In agreement with the other reports, co-incubation of the cells with EPA and PAL suppressed not only apoptosis ( Fig. 1 ) but also mitochondrial dysfunction (Fig. 2) caused by PAL in differentiated H9c2 cardiomyocytes.
Although Oh et al. have reported that n3-PUFA such as EPA exerts anti-inflammatory action through G protein-coupled receptor 120 (GPR120) on the cellular membrane [29] , the beneficial effects of EPA under our experimental conditions seem to take place in the cytosolic space. Because expression level of GPR120 is weak in The expression levels of dynamin-related protein 1 (Drp1), mitochondrial fission protein 1 (Fis1), mitochondrial fission factor (MFF), mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), and optic atrophy 1 (OPA1) were evaluated in each condition (CTL, PAL, EPA, and PAL+EPA: n=3-6). β-actin was used as an internal reference. Values represent the means ± SEM. * P < 0.05 and ** P < 0.01 vs CTL, † † P < 0.01 vs PAL (one-way ANOVA).
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myocytes [29] and GW9508, an agonist of GPR120, did not protect differentiated H9c2 myocytes from PAL-induced apoptosis in our experimental settings (Supplemental Fig. S2 ).
EPA protects myocytes through Drp1 downregulation
Accumulating evidence shows that aberrant mitochondrial dynamics are relevant to cardiac pathology, such as ischemia/reperfusion, cardiomyopathy, and heart failure [9, 30] . Our results also indicate that the PAL-induced lipotoxicity was accompanied by the aberrant mitochondrial dynamics (Fig. 3A and B) . In our experimental condition, an increased expression of Drp1 is more pronounced after PAL treatment among mitochondrial dynamics-related proteins (Fig. 3C) , although subtle decrease can be seen in Fis1 and MFF. The decrease in Fis1 and MFF after PAL may be the secondary reaction by the prominent increase in Drp1. Because the degradation of damaged mitochondrial requires the mitochondrial division in assistance of Drp1 and Fis1 and/ or MFF interaction [8] , the excessive mitochondrial division by Drp1- ) and total p38 (D) in each condition (CTL, PAL, EPA, and PAL+EPA: n=3-6). β-actin was used as an internal reference. Values represent the means ± SEM. * P < 0.05 and ** P < 0.01 vs CTL, † P < 0.05 and † † P < 0.01 vs PAL (one-way ANOVA). upregulation may result in the consumption of Fis1 and MFF. In addition, the Drp1 knockdown by siRNA attenuated mitochondrial fragmentation, apoptosis, and intracellular ATP depletion caused by PAL (Supplemental Fig. S1 ), in agreement with other reports [18, 31] . From these results, we assumed that Drp1 is one of major regulators of PAL-induced lipotoxicity. In addition, because our group previously demonstrated that mutual upregulation of Drp1 and ROS can promote mitochondrial dysfunction [15] , it is probable that PAL-induced ROS production, at least in part, contributes to Drp1 upregulation and mitochondrial dysfunction as a part of lipotoxicity. It is noteworthy that EPA treatment alone yielded relatively elongated mitochondria with reduced expression in Drp1 (Fig. 3) . This change (EPA-induced Drp1 downregulation) supports our hypothesis that EPA protects myocytes from PAL-induced apoptosis by modulating mitochondrial dynamicsrelated proteins (e.g., Drp1). Some reports suggested that phosphorylation of Drp1 at Ser 616 (positively) and at Ser 637 (negatively) affect its translocation to mitochondria [32, 33] . The contribution of phosphorylation of Drp1 to EPA-induced protection of myocytes cannot be completely ruled out in our experimental setting (Supplemental Fig. S3 ). Because the influence of total Drp1 expression was more significant than the Drp1 phosphorylation (at Ser 637 ), the effects of Drp1 phosphorylation were difficult to evaluate in the EPA-treated myocytes. Many other studies have already shown that ROS make a significant contribution to PAL-induced lipotoxicity [24, 25] . Hsu et al. demonstrated an antioxidant effect of EPA against doxorubicin-induced cardiotoxicity [34] . In contrast, the antioxidant effect of EPA seems to be negligible under our experimental conditions, because EPA alone neither reduced intracellular ROS (Fig. 2C ) nor altered expression of antioxidant enzymes SOD1 and SOD2 (Supplemental Fig. S4 ).
EPA suppresses Drp1 via activation of AMPK
AMPK is known as a major intracellular protein kinase that regulates not only cellular metabolism (fatty acid and glucose metabolism) but also anti-apoptotic process. In this study, we showed that AMPK activation by AICAR attenuated the PAL-induced Drp1 upregulation (Fig. 6C) and lipotoxicity ( Fig. 5C-E) . In addition, EPA activated AMPK phosphorylation (Fig. 4A) , whereas the AMPK knockdown by siRNA enhanced Drp1 upregulation ( Fig. 7A and B) and attenuated the EPA-mediated cardiac protection from adverse effects of PAL treatment (Fig. 7C and D) . AMPK may not be one and only Drp1 regulator, which can manipulate both in the upregulation and downregulation of Drp1, because, when cells were treated with PAL, Drp1 increased without significant AMPK downregulation (Fig. 4A) . Nevertheless, at least in our experimental condition, EPA suppressed Drp1 through an activation of AMPK, and then protected myocytes from the PAL-induced lipotoxicity.
Although some reports have suggested that PUFAs activate AMPK pathway and thereby protect cells from various adverse stimuli as demonstrated in adipocytes [35] , endothelial cells [36] , and cardiomyocyte [21] , the mechanism by which EPA activates AMPK is still unclear. Wu et al. reported that EPA upregulates uncoupling protein 2 (UCP2) via activation of peroxisome proliferator-activated receptor γ (PPARγ), and enhances the AMPK pathway by inhibiting ATP production in endothelial cells [37] . In contrast, in our experimental settings, neither the upregulation of UCPs (UCP2 and UCP3, Supplemental Fig.  S5 ) nor the inhibition of ATP production (Fig. 2B) was detected in the EPA-treated myocytes. Further research is needed to explore the precise mechanisms of AMPK activation by EPA.
Recent reports have suggested that, in endothelial cells [12, 38] and pancreatic β-cells [39] , the pharmacological activation of AMPK prevents the mitochondrial fragmentation by Ser 637 phosphorylation of Drp1, whereas alteration of the total amount of the Drp1 protein is negligible. Indeed, EPA may affect the Ser 637 phosphorylation in Drp1.
Although the downregulation of the total protein level of Drp1 was more pronounced under our experimental conditions, the increased ratio of phosphorylated Drp1 (Ser 637 ) to total Drp1 was also noticeable in the EPA-treated myocytes (Supplemental Fig. S3 ). In contrast to our results, Toyama et al. showed that the AMPKdependent mitochondrial fragmentation is activated by rapid inhibition of the electron transporter chain (within 1 h), and mitochondrial fragmentation can be reproduced by rapid pharmacological AMPK activation [40] . Because AMPK contributes to mitochondrial homeostasis through the activation of multiple signaling cascades [11] , the effects of AMPK activation on mitochondrial dynamics may depend on the types of extracellular stress and on stages of its action.
Emerging evidence indicates that activation of mitochondrial autophagy, termed "mitophagy", and mitochondrial quality control can afford myocardial protection from cardiac diseases [41] . Because AMPK is reported to activate autophagy [42] , the activation of AMPK by EPA can cause cardiac protection through mitophagy. Shirakabe et al. have reported that Drp1-dependent mitochondrial autophagy causes cardiac protection in a pressure overloaded heart [43] . At least in our experimental setting, the influence of Drp1-induced mitophagy on EPA-induced myocyte protection seems to be negligible because both pharmacological and EPA-induced activation of AMPK reduced Drp1 (Figs. 3C and 6C ). Conversely the Drp1 knockdown by siRNA protected cells from the PAL-induced lipotoxicity (Supplemental Fig.  S1 ). Furthermore, because excessive mitophagy may impair cellular metabolism, the significance of mitophagy is still controversial under several conditions [41] . Further research is needed to explore the causal relation between EPA-induced cell protection and mitophagy.
Experimental limitations
Although our study yielded significant pathophysiological findings regarding the EPA-mediated cardiac protection from lipotoxicity, careful consideration of the differences between myocardium and differentiated H9c2 myocytes is required. Thus, further in vivo experiments in animals and/or humans may be needed.
Conclusion
The results led us to conclude the following: (1) EPA protects myocytes from lipotoxicity, (2) EPA downregulates Drp1 and reduces mitochondrial fragmentation thereby protecting myocytes from lipotoxicity, and (3) EPA activates AMPK, which downregulates Drp1. Our findings give some clues to the mechanisms of EPA-mediated myocardial protection in HF.
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